Ra Pharmaceuticals (NASDAQ:RARX) Stock Upgrade
Ra Pharmaceuticals (NASDAQ:RARX) Shares were raised by research analysts at BidaskScore to a solid “Sell” rating in a research note revealed to investors and clients on 3 December.
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Ratings Coverage
Among 2 analysts covering Ra Pharmaceuticals (NASDAQ:RARX), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Ra Pharmaceuticals has $4800 highest and $4800 lowest target. $48’s average target is 2.43% above currents $46.86 stock price. Ra Pharmaceuticals had 9 analyst reports since June 21, 2019 according to SRatingsIntel. The stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has “Market Perform” rating given on Friday, October 11 by Leerink Swann. Stifel Nicolaus downgraded the stock to “Hold” rating in Friday, November 8 report.
The stock decreased 0.28% or $0.13 during the last trading session, reaching $46.86. About 434,893 shares traded. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has risen 210.02% since December 5, 2018 and is uptrending. It has outperformed by 210.02% the S&P500.
Analysts await Ra Pharmaceuticals, Inc. (NASDAQ:RARX) to report earnings on March, 5. They expect $-0.57 earnings per share, down 21.28 % or $0.10 from last year’s $-0.47 per share. After $-0.55 actual earnings per share reported by Ra Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.64 % negative EPS growth.
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company has market cap of $2.20 billion. The companyÂ’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. It currently has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).
More notable recent Ra Pharmaceuticals, Inc. (NASDAQ:RARX) news were published by: Benzinga.com which released: “Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of United Community, Highlands, MB Bancorp, and Ra Pharmaceuticals on behalf of Stockholders and Encourages Investors to Contact the Firm – Benzinga” on November 20, 2019, also Finance.Yahoo.com with their article: “Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Firm – Yahoo Finance” published on October 10, 2019, Finance.Yahoo.com published: “Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX) – Yahoo Finance” on June 19, 2019. More interesting news about Ra Pharmaceuticals, Inc. (NASDAQ:RARX) were released by: Prnewswire.com and their article: “Moore Kuehn, PLLC Encourages Liberty Property Trust (LPT), Proteon Therapeutics (PRTO), Ra Pharmaceuticals (RARX), Carolina Trust BancShares (CART), and Highlands Bankshares (HLND) Investors to Contact Firm – PRNewswire” published on December 03, 2019 as well as Seekingalpha.com‘s news article titled: “Ra Pharma prices stock offering at $32.50; shares down 2% premarket – Seeking Alpha” with publication date: July 24, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.